In CD34‐positive AML (n = 21) (defined as >2% CD34+ cells of the blast population), the percentage of CLEC12A‐positive CD34+CD38− cells amounted a median of 13·1% (range 0·0–58·9%), which was significantly different from NBM (P < 0·0001), but not from MDS BM (P = 0·08) (Fig 1B). This evidence concerns the gene CD34 and myelodysplastic syndrome.